Several previous studies demonstrated that DEPDC1B expression is abnormally upregulated in various cancer types, including pancreatic ductal adenocarcinoma,[16] bladder cancer,[17] prostate cancer,[15] hepatocellular cancer,[18] glioblastoma,[14] oral cancer,[11] and soft‐tissue sarcomas,[37] and is associated with poor prognosis, yet the mechanism underlying its dysregulation remains unclear. Here, DEPDC1B is linked to urinary bladder cancer.